At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 95 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Vehicle-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
In Brief
A Phase 3 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution for Allergic Conjunctivitis. Completed, enrolled 95 participants across 1 site.
Detailed Summary
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionFeb 2021
TodayJul 2026
First PostedDec 23, 2019
Enrollment StartDec 5, 2019
Primary CompletionFeb 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.5 years ago
Interventions
Reproxalap Ophthalmic Solution (0.25%)drug
Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
Vehicle Ophthalmic Solutiondrug
Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.